3 results
Approved WMOPending
To document that 8 weeks treatment with ledipasvir-sofosbuvir is effective in chronic HCV genotype 4 patients without cirrhosis.
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMOPending
Primary Objective: • To contrast Coherent Mapping quality (electrograms per map) and noise assessment using Octaray (with TRUEREF technology) versus Pentaray catheter for left and right atrium.Secondary Objective(s): • To contrast the Coherent…